Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Christine Chung

Christine Hwayong Chung, MD

Associate Professor of Oncology
Female
Appointment Phone

410-955-8964

Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Associate Professor of Oncology
  • Associate Professor of Otolaryngology-Head and Neck Surgery

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center

Expertise

Head and Neck Cancers, Human Papillomavirus Infections, Medical Oncology

Research Interests

head and neck cancers, HPV-associated head and neck cancers, viral oncology, epidermal growth factor receptors

Biography

Chung was selected following a national search for a physician-scientist to lead our translational and clinical research efforts in head and neck cancer. Previously, Chung was a faculty member at Vanderbilt University in the Division of Hematology and Oncology.

In addition to her role with our Upper Aerodigestive cancer program, Chung will work closely with investigators in our Viral Oncology program, where she will have a second, formal programmatic appointment.

Her research involves both laboratory translational and clinical investigation. A major focus of her laboratory research has been the study of epidermal growth factor receptor (EGFR) signal transduction and the mechanisms of resistance to EGFR inhibitors in the treatment of head and neck cancer (HNC). Chung also has focused on the roles of human papillomavirus (HPV) in the etiology of HNC. She has been a PI or co-PI of several completed and ongoing clinical trials.

She is co-chair of the Correlative Science and Translational Research Program of the Eastern Cooperative Oncology Group (ECOG) and she holds a similar leadership position on the Head and Neck Cancer Correlative Science and Translational Research Committee of the RTOG. Chung is a member of the Tumor Biology and Imaging Task Force for the Head and Neck Cancer Steering Committee of the National Cancer Institute.

Chung received a B.S. from UCLA, masters from Johns Hopkins, and her M.D. from Eastern Virginia Medical School. She entered the Physician-Scientist Research Pathway at UNC Chapel Hill where she completed combined Internal Medicine, Medical Oncology Fellowship and postdoctoral training in laboratory research under the mentorship of Charles Perou in 2004.

Languages

  • English
  • Korean
Additional Resources +
  • Education +

    Training

    • Eastern Virginia Medical School (Norfolk VA ) (1998)

    Residencies

    • University of North Carolina Hospitals / Internal Medicine (Chapel Hill NC ) (2002)

    Fellowships

    • Vanderbilt University School of Medicine / Hematology and Oncology (Nashville TN ) (2004)
    • University of North Carolina Hospitals / Medical Oncology (Chapel Hill NC ) (2003)

    Certifications

    • American Board of Internal Medicine / Internal Medicine (2011)
  • Research & Publications +

    Selected Publications

    Research Summary
    Dr. Chungs research involves both basic science and clinical/translational investigations. Her laboratory research primarily is focused on investigation of the epidermal growth factor receptor (EGFR) signal transduction and understanding the mechanisms of resistance to EGFR inhibitors in the treatment of head and neck cancer (HNC). She also studies the role of epithelial-to-mesenchymal transition and transforming growth factor-beta signaling in resistance to EGFR inhibition in HNC. In addition, she is investigating molecularly targeted approaches to treat patients with human papillomavirus-associated HNC in order to develop less toxic but effective agents. She applies the laboratory findings to develop phase I/II trials and correlative studies of novel anti-cancer treatments.

    Journal Citations
    Ang, K.K.; Harris, J.; Wheeler, R.; Weber, R.; Rosenthal, D.I.; Nguyen-Tan, P.F.; Westra, W.H.; Chung, C.H.; Jordan, R.C.; Lu, C.; Kim, H.; Axelrod, R.; Silverman, C.C.; Redmond, K.P.; Gillison, M.L. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35.

    Chou, Y.C.; Sheu, J.R.; Chung, C.L.; Chen, C.Y.; Lin, F.L.; Hsu, M.J.; Kuo, Y.H.; Hsiao, G. Nuclear-targeted inhibition of NF-kappaB on MMP-9 production by N-2-(4-bromophenyl) ethyl caffeamide in human monocytic cells. Chem Biol Interact. 2010 Mar 30;184(3):403-412.

    Chung, C.H.; Aulino, J.; Muldowney, N.J.; Hatakeyama, H.; Baumann, J.; Burkey, B.; Netterville, J.; Sinard, R.; Yarbrough, W.G.; Cmelak, A.J.; Slebos, R.J.; Shyr, Y.; Parker, J.; Gilbert, J.; Murphy, B.A. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2010 Apr;21(4):864-870.

    Chung, C.H.; Pohlmann, P.R.; Rothenberg, M.L.; Burkey, B.B.; Parker, J.; Palka, K.; Aulino, J.; Puzanov, I.; Murphy, B. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck. 2010 Jul 22.

    Chung, C.H.; Raben, D. p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancer. J Clin Oncol. 2010 Sep 20;28(27):4103-4104.

    Chung, C.H.; Seeley, E.H.; Roder, H.; Grigorieva, J.; Tsypin, M.; Roder, J.; Burtness, B.A.; Argiris, A.; Forastiere, A.A.; Gilbert, J.; Murphy, B.; Caprioli, R.M.; Carbone, D.P.; Cohen, E.E. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-365.

    Chung, C.H.; Zhang, Q.; Hammond, E.M.; Trotti, A.M., 3rd; Wang, H.; Spencer, S.; Zhang, H.Z.; Cooper, J.; Jordan, R.; Rotman, M.H.; Ang, K.K. Integrating Epidermal Growth Factor Receptor Assay with Clinical Parameters Improves Risk Classification for Relapse and Survival in Head-and-Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2010 Aug 21.

    Hatakeyama, H.; Cheng, H.; Wirth, P.; Counsell, A.; Marcrom, S.R.; Wood, C.B.; Pohlmann, P.R.; Gilbert, J.; Murphy, B.; Yarbrough, W.G.; Wheeler, D.L.; Harari, P.M.; Guo, Y.; Shyr, Y.; Slebos, R.J.; Chung, C.H. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One. 2010;5(9):e12702.

    Li, M.; Gray, W.; Zhang, H.; Chung, C.H.; Billheimer, D.; Yarbrough, W.G.; Liebler, D.C.; Shyr, Y.; Slebos, R.J. Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. J Proteome Res. 2010 Aug 6;9(8):4295-4305.

    Murphy, B.A.; Dietrich, M.S.; Wells, N.; Dwyer, K.; Ridner, S.H.; Silver, H.J.; Gilbert, J.; Chung, C.H.; Cmelak, A.; Burkey, B.; Yarbrough, W.G.; Sinard, R.; Netterville, J. Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation. Head Neck. 2010 Jan;32(1):26-37.

    Morrison, R.; Schleicher, S.M.; Sun, Y.; Niermann, K.J.; Kim, S.; Spratt, D.E.; Chung, C.H.; Lu, B. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol. 2011;2011:941876.

    Chung, C.H., Seeley, E., Roder, H., Grigorieva, J., Tsypin, M., Roder, J., Burtness, B., Argiris, A., Forastiere, A., Gilbert, J., Murphy, B., Caprioli, R., Carbone, D., and Cohen, E. 2010. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 19(2):358-65.
    Ang, K.K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D.I., Nguyen-Tan, P.F., Westra, W.H., Chung, C.H., Jordan, R.C., Lu, C., Kim, H., Axelrod, R., Silverman, C.C., Redmond, K.P., and Gillison, M.L. 2010. Human Papillomavirus (HPV) and survival of patients with oropharynx cancer. N Engl J Med. [Epub]
    Diaz, R., Jaboin, J., Morales-Paliza, M., Koehler, E., Phillips, J., Stinson, S., Gilbert, J., Chung, C.H., Murphy, B., Yarbrough, W., Murphy, P., Shyr, Y., and Cmelak, A. 2010. Hypothyroidism as a consequence of Intensity-Modulated Radiation Therapy with concurrent Taxane-based chemotherapy for locally-advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 77(2):468-76.
    Chung, C.H., Aulino, J., Muldowney, N.J., Hatakeyama, H., Baumann, J., Burkey, B., Netterville, J., Sinard, R., Yarbrough, W.G., Cmelak, A.J., Slebos, R., Shyr, Y., Parker, J., Gilbert, J., and Murphy, B.A. 2010. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 21(4):864-70.
    Murphy, B.A., Dietrich, M., Wells, N., Dwyer, K., Ridner, S., Silver, H., Gilbert, J., Chung, C.H., Cmelak, A., Burkey, B., Yarborough, W., Sinard, R., and Netterville, J. 2010. Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: A tool to assess symptom burden in patients treated with chemoradiation. Head Neck. 32(1):26-37.
    Cohen, E., Zhu, H., Lingen, M., Martin, L., Kuo, W-L., Choi, E., Kocherginsky, M., Parker, J., Chung, C.H., and Rosner, M. 2009. A feed-forward loop involving Protein Kinase C Alpha and microRNAs regulates tumor cell cycle. Cancer Res. 69(1):65-74.
    Bierie, B.*, Chung, C.H.*, Parker, J., Stover, D.G., Cheng, N., Chytil, A., Aakre, M., Shyr, Y., and Moses, H.L. 2009. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest. 119(6):1571-82. *These two authors share the first authorship.
    Baumann, J., Cohen, S., Evjen, A., Law, J., Vadivelu, S., Attia, A., Schindler, J., Chung, C.H., Wirth, P., Meijer, C., Snijders, P., Yarbrough, W., and Slebos, R. 2009. Human papillomavirus in early laryngeal carcinoma. Laryngoscope. 119(8):1531-7.
    Le, Q-T., Harris, J., Magliocco, A., Kong, C., Diaz, R., Shin, B., Cao, H., Trotti, A., Erler, J.T., Chung, C.H., Dicker, A., Pajak, T.F., Giaccia, A.J., and Ang, K.K. 2009. Validation of Lysyl Oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma Radiation Therapy Oncology Group Trial 90-03. J Clin Oncol. 27(26):4281-6.
    Slebos, R.J., Li, M., Vadivelu, S., Burkey, B.B., Netterville, J.L., Sinard, R., Gilbert, J., Murphy, B., Chung, C.H., Shyr, Y., and Yarbrough, W.G. 2008. Microsatellite mutations in buccal cells are associated with aging and head and neck carcinoma. Br J Cancer. 98(3):619-626.
    Chung, C.H., Mirakhur, B., Chan, E., Le, Q-T., Berlin, J., Morse, M., Murphy, B.A., Satinover, S., Hosen, J., Mauro, D., Slebos, R.J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D.J., and Platts-Mills, T.A. 2008. Cetuximab-induced anaphylaxis and IgE antibodies against galactose-alpha-1,3-galactose. N Engl J Med. 358(11):1109-1117.
    Gilbert, J., Cmelak, A., Shyr, Y., Netterville, J., Burkey, B., Sinard, R., Yarbrough, W., Chung, C.H., and Murphy, B. 2008. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Cancer. 113(1):186-192.
    Wang, S.E., Xiang, B., Guix, M., Olivares, M., Parker, J., Chung, C.H., Pandiella, A., and Arteaga, C.L. 2008. Transforming Growth Factor-beta engages TACE and ErbB3 to activate PI3K/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol. 28(18):5605-5620.
    Chung, C.H., Parker, J., Levy, S., Slebos, R.J., Dicker, A.P., and Rodeck, U. 2007. Gene expression profiles as markers of aggressive disease EGFR as a factor. Int J Radiat Oncol Biol Phys. 69(2S):S102-S105.
    Gilbert, J., Dang, T., Cmelak, A., Shyr, Y., Netterville, J., Burkey, B., Chung, C.H., Ikpeazu, C., and Murphy, B. 2007. Single agent Irinotecan for the treatment of metastatic or recurrent squamous carcinoma of the head and neck (SCCHN). Clin Med Oncol. 1:67-71.
    Slebos, R.J., Yi, Y., Ely, K., Carter, J., Evjen, A., Zhang, X., Shyr, Y., Murphy, B.M., Cmelak, A.J., Burkey, B.B., Netterville, J.L., Levy, S., Yarbrough, W.G., and Chung, C.H. 2006. Gene expression differences associated with HPV status in head and neck squamous cell carcinoma. Clin Cancer Res. 12(3):701-709.
    Chung, C.H., Parker, J.S., Ely, K., Carter, J., Yi, Y., Murphy, B.A., Ang, K.K., El-Naggar, A.K., Zanation, A.M., Cmelak, A.J., Levy, S., Slebos, R.J., and Yarbrough, W.G. 2006. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of Nuclear Factor-ĸB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 66(16):8210-8218.
    Chung, C.H., Ely, K., McGavran, L., Varella-Garcia, M., Parker, J., Parker, N., Jarrett, C., Carter, J., Murphy, B.A., Netterville, J., Burkey, B., Sinard, R., Cmelak, A., Levy, S., Yarbrough, W., Slebos, R.J., Hirsch, F.R. 2006. Increased EGFR gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 24(25):4170-4176.
    Chung, C.H., Parker, J.S., Karaca, G., Wu, J., Funkhouser, W.K., Moore, D., Xiang, D., Shockley, W., Weissler, W.C., Dressler, L.G., Shores, C.G., Yarbrough, W.G., Perou, C.M. 2004. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 5:489-500.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
  • Events +
  • Contact & Locations +

    Locations

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Appointment Phone: 410-955-8964
    Location Map

    Department/Division

    • Oncology

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.